Known targets — ChEMBL curated mechanism
ADRM1PSMA1PSMA2PSMA3PSMA4PSMA5PSMA6PSMA7PSMA8PSMB1PSMB10PSMB11PSMB2PSMB3PSMB4PSMB5PSMB6PSMB7PSMB8PSMB9PSMC1PSMC2PSMC3PSMC4PSMC5PSMC6PSMD1PSMD11PSMD12PSMD13PSMD14PSMD2PSMD3PSMD4PSMD6PSMD7PSMD8SEM1
The experimentally established mechanism targets of Carfilzomib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 known ✓ | P28074 | 17/20 | 1.00 |
| ▸ | PSMB9 known ✓ | P28065 | 3/20 | 1.00 |
| ▸ | PSMB8 known ✓ | P28062 | 3/20 | 1.00 |
| ▸ | PSMB10 known ✓ | P40306 | 3/20 | 1.00 |
| ▸ | PSMB2 known ✓ | P49721 | 3/20 | 1.00 |
| ▸ | PSMB11 known ✓ | A5LHX3 | 1/20 | 1.00 |
| ▸ | PSMD11 known ✓ | O00231 | 1/20 | 1.00 |
| ▸ | PSMD12 known ✓ | O00232 | 1/20 | 1.00 |
| ▸ | PSMD14 known ✓ | O00487 | 1/20 | 1.00 |
| ▸ | PSMA7 known ✓ | O14818 | 1/20 | 1.00 |
| ▸ | PSMD3 known ✓ | O43242 | 1/20 | 1.00 |
| ▸ | PSMC3 known ✓ | P17980 | 1/20 | 1.00 |
| ▸ | PSMB1 known ✓ | P20618 | 1/20 | 1.00 |
| ▸ | PSMA1 known ✓ | P25786 | 1/20 | 1.00 |
| ▸ | PSMA2 known ✓ | P25787 | 1/20 | 1.00 |
| ▸ | PSMA3 known ✓ | P25788 | 1/20 | 1.00 |
| ▸ | PSMA4 known ✓ | P25789 | 1/20 | 1.00 |
| ▸ | PSMA5 known ✓ | P28066 | 1/20 | 1.00 |
| ▸ | PSMB4 known ✓ | P28070 | 1/20 | 1.00 |
| ▸ | PSMB6 known ✓ | P28072 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carfilzomib SCHEMBL21036021 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL21036176 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL21036163 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL23616374 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL21036204 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL24140134 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL21367423 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL25438395 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL20825319 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 | |
| Carfilzomib SCHEMBL21350259 | 1.00 | PSMB5 (1.00) | PSMB5PSMB9PSMB8PSMB10PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800809-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2020-10-13 | — | — | US | disclosed |
| US-20190284231-A1 | PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2019-09-19 | — | — | US | disclosed |
| US-10301353-B2 | Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800809-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | SF3B5, PRCP, GBA1 | PSMB5 36/4885PSMB9 262/4885PSMB8 140/4885 |
| US-10301353-B2 | Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib | PRCP, ME1, MAN2B1 | PSMB5 91/4885PSMB9 105/4885PSMB8 130/4885 |
| US-20190284231-A1 | PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SF3B5, PRCP, GBA1 | PSMB5 36/4885PSMB9 262/4885PSMB8 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.